|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Onconova Therapeutics, Inc. (ONTX) |
|
|
$0.73 0.00 (0.00%) as of 4:30 Thu 5/20
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
179,650,000 |
| Market
Cap: |
131.14(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.73 - $0.73 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Onconova Therapeutics is a biopharmaceutical company focused on discovering and developing small molecule product candidates primarily to treat cancer. Co. has three clinical-stage product candidates and preclinical programs. Substantially all of Co.'s effort is focused on its primary product candidate, rigosertib, which has been tested in an intravenous formulation as a single agent for patients with higher-risk myelodysplastic syndromes (MDS), and an oral formulation as a single agent in lower risk MDS or in combination with azacitidine for patients with higher-risk MDS. Co.'s other product candidate, Briciclib, is a small molecule targeting an intracellular regulatory protein, Cyclin D1.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Marino James J |
Director |
– • – |
2018-02-08 |
4 |
B |
$0.00 |
$0 |
D/D |
50,000 |
86,321 |
2.31 |
- |
|
| Tyndall Capital Partners L P |
10% Owner |
– – • |
2018-02-08 |
4 |
B |
$1.01 |
$1,111,000 |
I/I |
1,100,000 |
2,097,022 |
1.5 |
- |
|
| Bienen Henry S |
Director |
– • – |
2017-04-26 |
4 |
B |
$2.10 |
$8,001 |
D/D |
3,810 |
12,724 |
2.39 |
- |
|
| Guerin Mark Patrick |
Chief Financial Officer |
• – – |
2017-04-26 |
4 |
B |
$2.10 |
$3,001 |
D/D |
1,429 |
5,155 |
2.66 |
- |
|
| Reddy E Premkumar |
Director |
– • – |
2017-04-26 |
4 |
B |
$2.10 |
$250,001 |
D/D |
119,048 |
385,832 |
2.39 |
- |
|
| Marino James J |
Director |
– • – |
2017-04-26 |
4 |
B |
$2.10 |
$25,003 |
D/D |
11,906 |
36,321 |
2.39 |
- |
|
| Kumar Ramesh |
President and CEO |
• • – |
2017-04-26 |
4 |
B |
$2.10 |
$50,001 |
D/D |
23,810 |
102,227 |
2.81 |
- |
|
| Tyndall Capital Partners L P |
10% Owner |
– – • |
2017-04-21 |
4 |
A |
$2.10 |
$999,999 |
I/I |
476,190 |
997,022 |
|
- |
|
| Marino James J |
Director |
– • – |
2016-08-01 |
4 |
OE |
$4.10 |
$100,060 |
D/D |
24,405 |
24,415 |
|
- |
|
| Tyndall Capital Partners L P |
10% Owner |
– – • |
2016-07-29 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
520,832 |
|
- |
|
| Bienen Henry S |
Director |
– • – |
2016-07-29 |
4 |
OE |
$4.10 |
$30,422 |
D/D |
7,420 |
8,914 |
|
- |
|
| Hoffman Michael B |
Director |
– • • |
2016-07-29 |
4 |
OE |
$4.10 |
$2,168,265 |
I/I |
528,845 |
980,673 |
|
- |
|
| Kumar Ramesh |
President and CEO |
• • – |
2016-07-29 |
4 |
OE |
$4.10 |
$208,136 |
D/D |
50,765 |
78,417 |
|
- |
|
| Fruchtman Steven M |
Chief Medical Officer |
• – – |
2016-07-29 |
4 |
OE |
$4.10 |
$25,732 |
D/D |
6,276 |
6,376 |
|
- |
|
| Reddy E Premkumar |
Director |
– • – |
2016-07-29 |
4 |
OE |
$4.10 |
$545,300 |
D/D |
133,000 |
266,784 |
|
- |
|
| Guerin Mark Patrick |
Chief Accounting Officer |
• – – |
2016-07-29 |
4 |
OE |
$4.10 |
$15,031 |
D/D |
3,666 |
3,726 |
|
- |
|
| Stover Jack E |
Director |
– • – |
2016-06-30 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
10 |
|
- |
|
| Maniar Manoj |
SVP - Product Development |
• – – |
2016-06-30 |
4 |
OE |
$6.50 |
$325 |
D/D |
50 |
50 |
|
- |
|
| Groopman Jerome |
Director |
– • – |
2016-06-29 |
4 |
OE |
$5.20 |
$52 |
D/D |
10 |
10 |
|
- |
|
| Marino James J |
Director |
– • – |
2016-06-27 |
4 |
OE |
$5.20 |
$52 |
D/D |
10 |
10 |
|
- |
|
| Fruchtman Steven M |
Chief Medical Officer |
• – – |
2016-06-24 |
4 |
OE |
$6.50 |
$650 |
D/D |
100 |
100 |
|
- |
|
| Baxalta Inc |
10% Owner |
– – • |
2015-05-06 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,603,295 |
|
- |
|
| Baxter Healthcare Sa |
10% Owner |
– – • |
2015-05-06 |
4 |
D |
$0.00 |
$0 |
D/D |
(2,603,295) |
0 |
|
- |
|
| Hoffman Michael B |
Director |
– • • |
2014-07-07 |
4 |
OE |
$2.67 |
$50,073 |
D/D |
18,754 |
18,754 |
|
- |
|
| Guerin Mark Patrick |
Chief Accounting OfficerOffice |
• – – |
2014-05-09 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
600 |
|
- |
|
181 Records found
|
|
Page 5 of 8 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
